Injective ($INJ) is approaching a key resistance zone as ETF expectations and network developments bring renewed attention to the token. After recovering from its August lows, $INJ is consolidating near $8, with buyers attempting to sustain the uptrend. Three U.S. ETF applications have strengthened the institutional-access narrative, while a proposed gas-fee upgrade targets transaction predictability. However, the immediate price question remains whether $INJ can break above $9 or face another rejection.
Injective ETF Hopes Strengthen Institutional Interest
Injective’s ETF narrative gained traction after three U.S. investment products tied to $INJ were filed by 21Shares, Canary Capital and REX-Osprey. The proposed products offer potential routes for traditional investors to gain exposure to the token, with some filings also involving staking.
Injective CEO Eric Chen said on October 5 that he expected U.S. $INJ ETFs to launch before 2027, although he did not provide a specific date. The applications remain subject to regulatory approval, and their eventual impact will depend on whether the products launch and attract meaningful inflows. For $INJ, the development creates a potential catalyst, but expectations alone do not guarantee sustained buying pressure.
coinpedia.org
